IFNG and non-small cell lung carcinoma: In spite of the low statistical power inherent in small cohorts of patient, we did see some evidence that clinical benefit from single-agent utomilumab was positively associated with biomarkers of T cells, cytotoxicity, and IFNg responses in NSCLC tumors.